Canopy Growth Corp

CGC ·Healthcare, Drug Manufacturers - General, Ontario, Canada
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Operating Activities
Net Income $-262.9M $-508.9M $-712.2M $-3.31B $-330.6M $-1.67B $-1.39B $-26.3M
Depreciation & Amortization
Depreciation $19.0M $21.5M $28.4M $55.6M $76.1M $70.9M $73.7M $30.1M
Amortization $17.4M $21.6M $24.8M $24.5M $34.8M $56.2M $51.3M $16.9M
Stock-Based Compensation $4.3M $-4.2M $14.2M $25.3M $46.7M $91.1M $320.3M $273.4M
Net Cash from Operating Activities $-63.8M $-165.8M $-282.0M $-557.5M $-545.8M $-465.7M $-772.6M $-535.0M
Investing Activities
Capital Expenditures $5.3M $10.8M $3.4M $9.1M $36.7M $164.5M $704.9M $644.5M
Business Acquisitions $24.2M
Net Cash from Investing Activities $-21.3M $-47.8M $241.6M $433.4M $230.8M $-884.1M $-347.7M $-3.23B
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $332.4M $148.7M $-465.1M $-19.7M $-45.5M $1.26B $-57.2M $5.85B
Net Change in Cash $250.9M $-56.5M $-506.7M $-99.0M $-378.6M $-148.5M $-1.18B $2.16B
Free Cash Flow $-69.1M $-176.6M $-285.4M $-566.7M $-582.5M $-630.2M $-1.48B $-1.18B
← Newer Page 1 of 2 Older →